Pillar 1 - FTO (new thread), page-977

Definitely a hot space!

this link I shared previously, although outdated (2019) I think is great at giving the short and skinny on the field https://cen.acs.org/business/start-ups/Epitranscriptomics-new-RNA-code-race/97/i7 and how the likes of Accent/ Storm and Gotham therapeutics all came into it. Appreciate you guys are all over it way more than I but thought I'd share again ha!

Quote from article I probably understood the most!
Robert Copeland, the president and chief scientific officer of Accent, acknowledges. The challenge for Accent and other companies will be to figure out which subset of people with leukemia would benefit from a METTL3 inhibitor, to lower m6A levels, and which would benefit from an FTO inhibitor, to raise m6A levels, Copeland explains. “If the pendulum swings too much one way or too much the other way, you can cause disease.”

Also, from the podcast with Dr Chuan He (https://activemotif.podbean.com/e/influence-of-dynamic-rna-methylation-on-gene-expression-chuan-he/) he mentioned they had disocvered a third eraser with the possibility of a 4th and 5th. He did mention a publication was going to be released on the third eraser but I never came across anything.